The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

**GOG-0218**: Bevacizumab is the first anti-angiogenic agent to demonstrate benefit in a population of newly diagnosed, previously untreated epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer patients following abdominal surgery for staging and maximal effort at tumor debulking; stage III (macroscopic residual disease) or stage IV disease. Front-line treatment of these patients with standard chemotherapy plus concurrent and maintenance bevacizumab was found to prolong progression-free survival.

**E2303**: The addition of cetuximab to standard adjuvant chemotherapy (mFOLFOX6) in wild-type KRAS patients with stage III colon cancer did not improve survival.
Cooperative Group Abstracts

Breast Cancer

ACOSOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/594
Protocol(s): ACOSOG-Z1041

http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA504
Other Participant(s): OTHER
Protocol(s): ACOSOG-Z0010

http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA513
Protocol(s): ACOSOG-Z1031

http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA506
Other Participant(s): NCCTG
Protocol(s): ACOSOG-Z0011

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS118
Protocol(s): ACOSOG-Z1071
CALGB

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/507
Other Participant(s): ECOG, RTOG
Protocol(s): CALGB-9343

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS110
Protocol(s): CALGB-40603

ECOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1005
Protocol(s): E2100

NCCTG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/565
Protocol(s): N083E

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS129
Protocol(s): N0733

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1157
Protocol(s): Multiple Trials
NCIC Clinical Trials Group

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1578  
Protocol(s): NCIC-MA.21

NSABP

http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA505  
Protocol(s): NSABP-B-32

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1524  
Protocol(s): NSABP-P-1

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/509  
Protocol(s): NSABP-B-14, NSABP-B-20

SWOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/511  
Other Participant(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group  
Protocol(s): INT-0100

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1006  
Protocol(s): S0430
CNS Cancer

COG

Ashley D: Systemic chemotherapy, second look surgery and conformal radiation therapy limited to the posterior fossa and primary site for children > 8 months and < 3 years with nonmetastatic medulloblastoma: a Children’s Oncology Group phase III study, follow up rep. International Symposium on Pediatric Neuro-Oncology, Vienna, Austria, Jun, 2010.  
http://www.ispno2010.com/  
Protocol(s): POG-9233

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9539  
Protocol(s): ACNS0223

http://www.ispno2010.com/  
Protocol(s): ACNS0223

http://www.ispno2010.com/  
Protocol(s): ACNS0122

http://www.ispno2010.com/  
Protocol(s): ACNS0423

http://www.ispno2010.com/  
Protocol(s): ADVL0515

http://www.ispno2010.com/  
Protocol(s): A9961
Protocol(s): A9961

**NCCTG**

Protocol(s): N0776

Protocol(s): N027D

**RTOG**

Protocol(s): RTOG-0211

Protocol(s): RTOG-0625

Gastrointestinal Cancer

**ACOSOG**

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/10006](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/10006)

Protocol(s): ACOSOG-Z9001

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3510](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3510)

Protocol(s): ACOSOG-Z6041

**ACRIN**

[http://university.asco.org/CT2010](http://university.asco.org/CT2010)

Protocol(s): ACRIN-6664

**CALGB**

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4006](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4006)

Other Participant(s): ECOG

Protocol(s): CALGB-80403

**COG**

[http://www.abstractsonline.com/Plan/ViewAbstract.aspx?eKey=6039ff3d-549f-45ce-821e-9687d5d7b642&cKey=6aad66bf-4b49-4ff2-9d69-46f3fd829da0&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?eKey=6039ff3d-549f-45ce-821e-9687d5d7b642&cKey=6aad66bf-4b49-4ff2-9d69-46f3fd829da0&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d)

Protocol(s): AEPI04C1

[http://www.abstractsonline.com/Plan/ViewAbstract.aspx?eKey=c631cc32-da11-432c-86fc-8d5f23ef6d870&cKey=f0fba763-41a8-4721-a0f8-3742fb1ce356&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?eKey=c631cc32-da11-432c-86fc-8d5f23ef6d870&cKey=f0fba763-41a8-4721-a0f8-3742fb1ce356&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d)

Protocol(s): AEPI04C1
ECOG

Berlin JD, Catalano P, Feng Y, Lowy AM, Blackstock AW, Philip PA, McWilliams RR, Abbruzzese JL, Benson AB: ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely-resected pancreatic adenocarcinoma. J Clin Oncol 2010; 28(15s): Abst. 4034.  
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4034  
Other Participant(s): CALGB, NCCTG, SWOG  
Protocol(s): E2204

Gibson MK, Catalano P, Kleinberg LR, Staley CA, Montgomery EA, Song W, Mulcahy MF, Leichman LP, Benson AB: E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. J Clin Oncol 2010; 28(15s): Abst. 4064.  
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4064  
Protocol(s): E2205

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2414  
Other Participant(s): CALGB, NCCTG, SWOG  
Protocol(s): INT-0089, N994C

NCCTG

Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S: Adjuvant mFOLFOX6 with or without cetuximab (Cmb) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010; 28(18s): Abst. CRA3507.  
http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA3507  
Protocol(s): N0147

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3616  
Other Participant(s): CALGB, ECOG, NSABP, SWOG  
Protocol(s): INT-0089, N0441, NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3520
Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG
Protocol(s): N9741

Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, Gill S, Kahlenberg MS, Nair S, Alberts SR: Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010; 28(15s): Abst. 3508.
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3508
Protocol(s): N0147

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3549
Protocol(s): N054C

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3518
Other Participant(s): CALGB, ECOG, NSABP, SWOG
Protocol(s): INT-0089, N994C, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3523
Other Participant(s): CALGB, ECOG, NSABP, SWOG
Protocol(s): INT-0089, N0441, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3519
Other Participant(s): CALGB, ECOG, NSABP, SWOG
Protocol(s): INT-0089, N994C, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2351
Protocol(s): N994C
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=c6b7ae88-944b-4414-83af-25e4306e08fa&cKey=4addbc97-064c-4bcd-b958-c11e9f211bf2&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d
Protocol(s): N994C

NSABP

http://meeting.ascopubs.org/cgi/content/abstract/28/15_supp/9035
Protocol(s): NSABP-LTS-01

McCahill LE, Yothers GA, Sharif S, Petrelli NJ, Lopa S, O’Connell MJ, Wolmark N: A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10. J Clin Oncol 2010; 28(15s): Abst. 3527. 
http://meeting.ascopubs.org/cgi/content/abstract/28/15_supp/3527
Protocol(s): NSABP-C-10

http://meeting.ascopubs.org/cgi/content/abstract/28/15_supp/3503
Protocol(s): NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2334
Protocol(s): NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06

http://meeting.ascopubs.org/cgi/content/abstract/28/15_supp/3516
Protocol(s): NSABP-C-07
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2353
Protocol(s): NSABP-C-07

RTOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1297
Other Participant(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, SWOG
Protocol(s): RTOG-98-11

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1606
Protocol(s): RTOG-0529

SWOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3640
Other Participant(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, RTOG
Protocol(s): INT-0144

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS223
Protocol(s): S0727

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2202
Protocol(s): S0727

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1091
Protocol(s): S0414

Genitourinary Cancer

**CALGB**


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4525
Protocol(s): CALGB-90206


http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA4511
Other Participant(s): ECOG
Protocol(s): CALGB-90401

**ECOG**


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4668
Protocol(s): E5803


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4556
Protocol(s): E5805

**NCCTG**


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9139
Protocol(s): N00CB
NCIC Clinical Trials Group

http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/CRA4504  
Other Participant(s): CALGB, ECOG, SWOG  
Protocol(s): T94-0110, CR-94-023

RTOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30652

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4632

SWOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS342

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30449

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER  
Protocol(s): INT-0105, INT-0162
http://www.jurology.com/article/S0022-5347(10)01818-5/fulltext  
Protocol(s): SWOG-4B951

Other Participant(s): CALGB, ECOG, OTHER  
Protocol(s): S9917

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30750  
Other Participant(s): CALGB, ECOG  
Protocol(s): INT-0080

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4569  
Protocol(s): S0028

http://www.jurology.com/article/S0022-5347(10)01811-2/fulltext  
Other Participant(s): CALGB, ECOG  
Protocol(s): INT-0080

Other Participant(s): CALGB, OTHER  
Protocol(s): S9921
Gynecologic Cancer

**GOG**


http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-
18&cd=68148&user=23918958&pi=90090958090010142&orig=browse&coverDate=03%2F31%2F2010&sk=998839996.8998&view&v&d&ie=/sdarticle.pdf

Protocol(s): GOG-0170I


http://meeting.asco.org/cgi/content/abstract/28/18_suppl/LBA1

Protocol(s): GOG-0218


http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-
18&cd=68148&user=23918958&pi=90090958090010142&orig=browse&coverDate=03%2F31%2F2010&sk=998839996.8998&view&v&d&ie=/sdarticle.pdf

Protocol(s): GOG-0157


http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-
18&cd=68148&user=23918958&pi=90090958090010142&orig=browse&coverDate=03%2F31%2F2010&sk=998839996.8998&view&v&d&ie=/sdarticle.pdf

Protocol(s): GOG-0157


http://meeting.asco.org/cgi/content/abstract/28/15_suppl/5010

Protocol(s): GOG-0126R


http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-
18&cd=68148&user=23918958&pi=90090958090010142&orig=browse&coverDate=03%2F31%2F2010&sk=998839996.8998&view&v&d&ie=/sdarticle.pdf

Protocol(s): GOG-0120


Protocol(s): GOG-0171

Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, De Geest K, Cohn DE, Monk BJ, Michael H: GOG 175: A randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 Q 21 days x 3 courses plus low dose paclitaxel 40 mg/m2/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 Q 21 days x 3 courses plus observation in patients with early stage ovarian cancer. Gynecologic Oncology 2010; 116(3): Abst. 1.  
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-16&_cdi=6814&_user=2391895&_pii=S0090825809010142&_origin=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVib-zSKA&mds=1f4f44cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf  
Protocol(s): GOG-0175

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-16&_cdi=6814&_user=2391895&_pii=S0090825809010142&_origin=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVib-zSKA&mds=1f4f44cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf  
Other Participant(s): ECOG, SWOG  
Protocol(s): GOG-0114

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5046  
Protocol(s): GOG-0186F

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-16&_cdi=6814&_user=2391895&_pii=S0090825809010142&_origin=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVib-zSKA&mds=1f4f44cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf  
Protocol(s): GOG-9917

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4YDSNXV-3-16&_cdi=6814&_user=2391895&_pii=S0090825809010142&_origin=browse&_coverDate=03%2F31%2F2010&_sk=998839996.8998&view=c&wchp=dGLbVib-zSKA&mds=1f4f44cf3c0ca69aa057195403495c7d&ie=/sdarticle.pdf  
Protocol(s): GOG-0172
Protocol(s): Multiple Trials

http://www.sciencedirect.com/science?ob=Mimg&imagekey=B6WG6-4YDSNXV-3-18_cdi=6814&user=2391895&pij=500908258090101428&orig=browse__coverDate=03%2F31%2F2010_sk=99883996.8998&view=c&wchp=dGLbV0b-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7&ie=sdarticle.pdf
Protocol(s): GOG-0122

http://www.sciencedirect.com/science?ob=Mimg&imagekey=B6WG6-4YDSNXV-3-18_cdi=6814&user=2391895&pij=500908258090101428&orig=browse__coverDate=03%2F31%2F2010_sk=99883996.8998&view=c&wchp=dGLbV0b-zSkWA&md5=1f4414cf3c0ca69aa057195403495c7&ie=sdarticle.pdf
Protocol(s): GOG-0170J

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5075
Protocol(s): GOG-0172

http://www.sciencedirect.com/science?ob=Mimg&imagekey=B6WG6-4YRY9XG-3-18_cdi=6814&user=2391895&pij=500908258090101426&orig=browse__coverDate=05%2F31%2F2010_sk=998829997&view=c&wchp=dGLbVib-zSkWA&md5=8d9c6ec94bd202ff93880693889406c9&ie=sdarticle.pdf
Other Participant(s): OTHER
Protocol(s): GOG-LAP2

Protocol(s): GOG-0211
**NCCTG**

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9024  
Protocol(s): N04CA

**NCIC Clinical Trials Group**

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3090  
Protocol(s): NCIC-160

**RTOG**

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5006  
Protocol(s): RTOG-0417

**Head and Neck Cancer**

**ECOG**

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5537  
Protocol(s): E3303

Wanebo HJ, Ghebremichael M, Burtness BA, Spencer SA, Ridge JA, Forastiere AA: Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). J Clin Oncol 2010; 28(15s): Abst. 5513.  
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5513  
Protocol(s): E2303
RTOG


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5507

Protocol(s): RTOG-0129


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5552

Protocol(s): RTOG-90-03


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5510

Protocol(s): RTOG-90-03


Protocol(s): RTOG-0129


Protocol(s): RTOG-99-11

SWOG


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5555

Protocol(s): S0329
Leukemia, Myelodysplasia, and Transplantation

**CALGB**

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6531](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6531)  
Protocol(s): CALGB-8923, CALGB-8525, CALGB-9720, CALGB-10201

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9510](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9510)  
Other Participant(s): COG, ECOG, NCIC Clinical Trials Group, SWOG  
Protocol(s): C9710

[http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3a98c08e-5100-427d-b077-f6c5984fe483&cKey=c8810c49-daee-4de8-8e66-da436a046dd0&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3a98c08e-5100-427d-b077-f6c5984fe483&cKey=c8810c49-daee-4de8-8e66-da436a046dd0&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d)  
Protocol(s): Multiple Trials

**COG**

[http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART)  
Protocol(s): POG-9906

[http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART)  
Protocol(s): POG-9404

[http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART)  
Protocol(s): AALL0232, AALL0331, AALL03B1
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9521  
Protocol(s): AALL03B1, AALL05B1, POG-9900

http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART  
Protocol(s): AALL03B1, AALL05B1, POG-9900

http://aje.oxfordjournals.org/cgi/reprint/171/suppl_11/S1  
Protocol(s): Multiple Trials

http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART  
Protocol(s): AALL03B1

Protocol(s): CCG-1961

http://stjude.org/SJFile/Final%20Brochure.pdf  
Protocol(s): CCG-1961

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9515  
Protocol(s): CCG-1961

http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART  
Protocol(s): CCG-2961
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9509
Protocol(s): AALL0232

http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART
Protocol(s): AALL0031

Lung Cancer

ACOSOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7021
Protocol(s): ACOSOG-Z0030

ACRIN

Protocol(s): ACRIN-6654

Protocol(s): ACRIN-6678

Protocol(s): ACRIN-6654
CALGB


Other Participant(s): NCCTG, RTOG
Protocol(s): CALGB-9633


Protocol(s): CALGB-30406


Protocol(s): CALGB-30601


Protocol(s): CALGB-30406


Protocol(s): CALGB-30504


Protocol(s): CALGB-150607

ECOG


Protocol(s): E2Z02

Other Participant(s): CALGB, NCCTG, NCIC Clinical Trials Group, RTOG, SWOG
Protocol(s): E5597


Protocol(s): E1504


Protocol(s): E2501

NCCTG


Protocol(s): N0723


Protocol(s): N0528


Protocol(s): Multiple Trials


Protocol(s): Multiple Trials
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7085
Protocol(s): N0321

**NCIC Clinical Trials Group**

http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA7005
Protocol(s): NCIC-BR.19

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=49b3a7a1-b6e0-43fe-b43c-e5742f53b9a6&cKey=3d8e63fc-b617-4a11-8bd3-1ef291e44ede
Other Participant(s): CALGB, ECOG, SWOG
Protocol(s): JBR10

**RTOG**

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7024
Protocol(s): RTOG 0229

**SWOG**

http://ajrccm.atsjournals.org/cgi/reprint/181/1_MeetingAbstracts/A6765
Other Participant(s): CALGB, ECOG, NCCTG, RTOG
Protocol(s): S0000
Lymphoma and Plasma Cell Disorders

**CALGB**

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS306](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS306)  
Protocol(s): CALGB-50403

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8017](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8017)  
Other Participant(s): ECOG  
Protocol(s): CALGB-100104

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8106](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8106)  
Protocol(s): CALGB-50501

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8039](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8039)  
Protocol(s): CALGB-50602

**COG**

[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9536](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9536)  
Protocol(s): ANHL01P1

Goldman SC, Lynch J, Harrison L, Cairo M: A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B) and high-risk (Group C) mature B-NHL: A Children's Oncology Group report. J Clin Oncol 2010; 28(15s): Abst. 9572.  
[http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9572](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9572)  
Protocol(s): ANHL01P1
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9537
Protocol(s): AHOD0521

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9511
Protocol(s): ANHL0131

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9527
Protocol(s): ANHL01P1

ECOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/10546
Protocol(s): E4A03

SWOG

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group
Protocol(s): S9704

Sanchorawala V, Bolejack V, Crowley J, Hoering A, Finn KT, Fennessey S, Seldin DC, Barlogie B: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial. J Clin Oncol 2010; 28(15s): Abst. 8022.
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8022
Protocol(s): S0115
Melanoma/Skin Cancers

**ECOG**


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8511  
Protocol(s): E2603


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS312  
Protocol(s): E2607


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8504  
Other Participant(s): CALGB, SWOG  
Protocol(s): E4697


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8508  
Protocol(s): E1602

**NCCTG**


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8572  
Protocol(s): N0675


http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8578  
Protocol(s): N057E
SWOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8502
Other Participant(s): ECOG
Protocol(s): S0438

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8517
Other Participant(s): CALGB, COG, ECOG
Protocol(s): S0008

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8513
Other Participant(s): CALGB, COG, ECOG
Protocol(s): S0008

Other Cancer

ACRIN

http://university.asco.org/CT2010
Protocol(s): Multiple Trials

CALGB

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6148
Protocol(s): Multiple Trials

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3021
Protocol(s): CALGB-40101
COG

http://www.anr2010.com/
Protocol(s): Multiple Trials

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9512
Protocol(s): ALTE03N1

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9518
Protocol(s): Multiple Trials

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9517
Protocol(s): ANBL00B1

http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART
Protocol(s): ANBL00B1

http://www.anr2010.com/
Protocol(s): Multiple Trials
http://www.anr2010.com/  
Protocol(s): Multiple Trials

http://aje.oxfordjournals.org/cgi/reprint/171/suppl_11/S1  
Protocol(s): Multiple Trials

http://www.anr2010.com/  
Protocol(s): P9462

http://meeting.asccopubs.org/cgi/content/abstract/28/15_suppl/9529  
Protocol(s): ADVL0812

http://aje.oxfordjournals.org/cgi/reprint/171/suppl_11/S1  
Protocol(s): AE22

http://www.anr2010.com/  
Protocol(s): A3973

Protocol(s): ANUR0631
Protocol(s): ANUR0631

Protocol(s): A3973

Protocol(s): A3973

Protocol(s): CCG-3891

Protocol(s): ADVL0714

Protocol(s): ANBL00B1

Protocol(s): ANUR0631

Protocol(s): ADVL0525
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9516
Protocol(s): A3973

http://www.anr2010.com/
Protocol(s): A3973

ECOG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9120
Protocol(s): E2Z02

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9118
Protocol(s): E2Z02

NCCTG

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9018
Protocol(s): N0993

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9004
Protocol(s): N05C7

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9135
Protocol(s): NCCTG-N08C1
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6108
Protocol(s): NCCTG-89-20-52

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9017
Protocol(s): N05C5

RTOG

Protocol(s): RTOG-0813

http://university.asco.org/CT2010
Protocol(s): Multiple Trials

http://university.asco.org/CT2010
Protocol(s): RTOG-0215

http://university.asco.org/CT2010
Protocol(s): Multiple Trials

http://university.asco.org/CT2010
Protocol(s): Multiple Trials
**SWOG**

Other Participant(s): CALGB, ECOG, NCCTG, RTOG
Protocol(s): S0000

http://university.asco.org/CT2010
Other Participant(s): CALGB, ECOG, NCCTG, RTOG
Protocol(s): S0000

Other Participant(s): CALGB, ECOG, NCCTG, RTOG
Protocol(s): S0000

http://university.asco.org/CT2010
Other Participant(s): CALGB, ECOG, NCCTG, RTOG
Protocol(s): S0000

Other Participant(s): CALGB, ECOG, NCCTG, RTOG
Protocol(s): S0000

**Sarcoma/Bone and Soft Tissue Cancers**

**COG**

http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART
Protocol(s): AOST0221
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9552  
Protocol(s): AEWS0521

http://www3.interscience.wiley.com/cgi-bin/fulltext/123320003/PDFSTART  
Protocol(s): INT-0117, INT-0118, D9602, INT-0119

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9504  
Protocol(s): D9803

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=937e2d4b-4992-420f-833d-358b59b869e0&cKey=2db70d99-39aa-43c7-a84e-0c6bef7b2bd1&kKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d  
Protocol(s): AEWS0031

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9503  
Protocol(s): ARST0431
NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators


http://www.anr2010.com/

http://ajrccm.atsjournals.org/cgi/reprint/181/1_MeetingAbstracts/A6765

http://university.asco.org/CT2010

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e16505

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9120

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS129

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=c278f6aa-8185-4c9c-a957-ea12be9a7e18&cKey=a183115e-b965-4002-a19f-9d22c0ab1375&mKey=%7b0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7d


DCTD and DCP Activities

**Scientific**


**Disclaimer:** References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.